Global to push GA events into
skip to main content

Title: Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging

Antibodies against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide. No Drawings
Inventors:
Issue Date:
OSTI Identifier:
6925998
Assignee:
Rhomed Inc., Albuquerque, NM (United States) PTO; EDB-94-155141
Patent Number(s):
US 5346687; A
Application Number:
PPN: US 7-816476
Contract Number:
FG04-89ER60899
Resource Relation:
Patent File Date: 3 Jan 1992
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIBODIES; LABELLING; ANTIGEN-ANTIBODY REACTIONS; DIAGNOSTIC USES; IMAGE PROCESSING; PROCESSING; USES 550601* -- Medicine-- Unsealed Radionuclides in Diagnostics